CL2020003218A1 - Anticuerpos dirigidos contra il-11ra - Google Patents
Anticuerpos dirigidos contra il-11raInfo
- Publication number
- CL2020003218A1 CL2020003218A1 CL2020003218A CL2020003218A CL2020003218A1 CL 2020003218 A1 CL2020003218 A1 CL 2020003218A1 CL 2020003218 A CL2020003218 A CL 2020003218A CL 2020003218 A CL2020003218 A CL 2020003218A CL 2020003218 A1 CL2020003218 A1 CL 2020003218A1
- Authority
- CL
- Chile
- Prior art keywords
- directed against
- antibodies directed
- binding
- prophylaxis
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
Abstract
Se proporcionan moléculas de unión a antígeno capaces de unirse a IL-11Ra y procedimientos de tratamiento médico y profilaxis usando las mismas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1809700.6A GB201809700D0 (en) | 2018-06-13 | 2018-06-13 | IL-11 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020003218A1 true CL2020003218A1 (es) | 2021-07-30 |
Family
ID=63042296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020003218A CL2020003218A1 (es) | 2018-06-13 | 2020-12-11 | Anticuerpos dirigidos contra il-11ra |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11084878B2 (es) |
| EP (1) | EP3806959A1 (es) |
| JP (1) | JP7437325B2 (es) |
| KR (1) | KR20210031645A (es) |
| CN (1) | CN113226471B (es) |
| AU (1) | AU2019286797A1 (es) |
| BR (1) | BR112020025502A2 (es) |
| CA (1) | CA3101401A1 (es) |
| CL (1) | CL2020003218A1 (es) |
| CO (1) | CO2020015376A2 (es) |
| CR (1) | CR20210010A (es) |
| DO (1) | DOP2020000236A (es) |
| EA (1) | EA202092605A1 (es) |
| EC (1) | ECSP21001499A (es) |
| GB (1) | GB201809700D0 (es) |
| IL (1) | IL279352A (es) |
| JO (1) | JOP20200300A1 (es) |
| MA (1) | MA52885A (es) |
| MX (1) | MX2020013468A (es) |
| PE (1) | PE20211500A1 (es) |
| PH (1) | PH12020552229A1 (es) |
| SG (1) | SG11202011648UA (es) |
| TW (1) | TW202016140A (es) |
| WO (1) | WO2019238884A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201522186D0 (en) | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
| CA3045871A1 (en) | 2016-12-16 | 2018-06-21 | Singapore Health Services Pte Ltd | Il-11 antibodies |
| GB201621439D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore | IL-11Ra Antibodies |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| WO2020152122A1 (en) | 2019-01-21 | 2020-07-30 | Singapore Health Services Pte. Ltd. | Treatment of hepatotoxicity |
| GB201902419D0 (en) | 2019-02-22 | 2019-04-10 | Singapore Health Serv Pte Ltd | Treatment of kidney injury |
| WO2020225147A1 (en) | 2019-05-03 | 2020-11-12 | Singapore Health Services Pte. Ltd. | Treatment and prevention of metabolic diseases |
| GB202009292D0 (en) | 2020-06-18 | 2020-08-05 | Singapore Health Serv Pte Ltd | Treatment and prevention of disease caused by type IV collagen dysfunction |
| EP3939999A1 (en) * | 2020-07-14 | 2022-01-19 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof |
| GB202017244D0 (en) | 2020-10-30 | 2020-12-16 | Nat Univ Singapore | Methods to extend health-span and treat age-related diseases |
| US20240317847A1 (en) | 2021-02-26 | 2024-09-26 | Bayer Aktiengesellschaft | INHIBITORS OF IL-11 OR IL-11Ra FOR USE IN THE TREATMENT OF ABNORMAL UTERINE BLEEDING |
| JP2024524301A (ja) * | 2021-07-02 | 2024-07-05 | ラエクナ セラピューティクス シャンハイ カンパニー リミテッド | 活性化肝星細胞（ｈｓｃ）の枯渇及びその使用 |
| US20250092126A1 (en) | 2021-07-26 | 2025-03-20 | Boehringer Ingelheim International Gmbh | Treatment and prevention of alcoholic liver disease |
| EP4396236A4 (en) * | 2021-08-30 | 2025-10-01 | Lassen Therapeutics 1 Inc | ANTI-IL-11R ALPHA ANTIBODIES |
| CN113735975B (zh) * | 2021-09-07 | 2022-08-12 | 广东东阳光药业有限公司 | 一种抗il-11r抗体及其应用 |
| EP4448096A1 (en) | 2021-12-16 | 2024-10-23 | Singapore Health Services Pte. Ltd. | Treatment and prevention of glomerular disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1598364A1 (en) * | 2004-05-21 | 2005-11-23 | AGIRx Limited | Chimerical soluble hyper IL-11 receptor and use thereof |
| FI2953971T3 (fi) * | 2013-02-07 | 2023-04-27 | Csl Ltd | Il-11r-sitojaproteiineja ja niiden käyttöjä |
| JP7264592B2 (ja) * | 2015-01-26 | 2023-04-25 | ザ ユニバーシティー オブ シカゴ | ＩＬ１３Ｒα２結合剤及び癌治療におけるその使用 |
| GB201522186D0 (en) * | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
| GB201621439D0 (en) * | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore | IL-11Ra Antibodies |
-
2018
- 2018-06-13 GB GBGB1809700.6A patent/GB201809700D0/en not_active Ceased
-
2019
- 2019-06-13 PE PE2020001991A patent/PE20211500A1/es unknown
- 2019-06-13 BR BR112020025502-5A patent/BR112020025502A2/pt not_active Application Discontinuation
- 2019-06-13 JP JP2020568983A patent/JP7437325B2/ja active Active
- 2019-06-13 CR CR20210010A patent/CR20210010A/es unknown
- 2019-06-13 AU AU2019286797A patent/AU2019286797A1/en not_active Abandoned
- 2019-06-13 MA MA052885A patent/MA52885A/fr unknown
- 2019-06-13 MX MX2020013468A patent/MX2020013468A/es unknown
- 2019-06-13 CN CN201980040141.7A patent/CN113226471B/zh active Active
- 2019-06-13 JO JOP/2020/0300A patent/JOP20200300A1/ar unknown
- 2019-06-13 TW TW108120517A patent/TW202016140A/zh unknown
- 2019-06-13 US US16/440,876 patent/US11084878B2/en active Active
- 2019-06-13 KR KR1020207037233A patent/KR20210031645A/ko not_active Ceased
- 2019-06-13 WO PCT/EP2019/065600 patent/WO2019238884A1/en not_active Ceased
- 2019-06-13 CA CA3101401A patent/CA3101401A1/en active Pending
- 2019-06-13 EP EP19734286.8A patent/EP3806959A1/en active Pending
- 2019-06-13 SG SG11202011648UA patent/SG11202011648UA/en unknown
- 2019-06-13 EA EA202092605A patent/EA202092605A1/ru unknown
-
2020
- 2020-12-04 DO DO2020000236A patent/DOP2020000236A/es unknown
- 2020-12-09 CO CONC2020/0015376A patent/CO2020015376A2/es unknown
- 2020-12-10 IL IL279352A patent/IL279352A/en unknown
- 2020-12-11 CL CL2020003218A patent/CL2020003218A1/es unknown
- 2020-12-13 PH PH12020552229A patent/PH12020552229A1/en unknown
-
2021
- 2021-01-08 EC ECSENADI20211499A patent/ECSP21001499A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202016140A (zh) | 2020-05-01 |
| PE20211500A1 (es) | 2021-08-11 |
| IL279352A (en) | 2021-01-31 |
| AU2019286797A1 (en) | 2021-01-28 |
| DOP2020000236A (es) | 2021-10-31 |
| US11084878B2 (en) | 2021-08-10 |
| MX2020013468A (es) | 2021-04-13 |
| US20190389957A1 (en) | 2019-12-26 |
| EA202092605A1 (ru) | 2021-06-01 |
| US20200377605A9 (en) | 2020-12-03 |
| JP2021527086A (ja) | 2021-10-11 |
| ECSP21001499A (es) | 2021-03-31 |
| CA3101401A1 (en) | 2019-12-19 |
| CN113226471B (zh) | 2025-01-28 |
| EP3806959A1 (en) | 2021-04-21 |
| CO2020015376A2 (es) | 2021-04-19 |
| SG11202011648UA (en) | 2020-12-30 |
| KR20210031645A (ko) | 2021-03-22 |
| BR112020025502A2 (pt) | 2021-03-16 |
| JOP20200300A1 (ar) | 2020-11-22 |
| WO2019238884A1 (en) | 2019-12-19 |
| PH12020552229A1 (en) | 2021-06-28 |
| JP7437325B2 (ja) | 2024-02-22 |
| GB201809700D0 (en) | 2018-08-01 |
| MA52885A (fr) | 2021-04-21 |
| CR20210010A (es) | 2021-06-01 |
| CN113226471A (zh) | 2021-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21000695A (es) | Anticuerpos dirigidos contra il-11 | |
| CL2020003218A1 (es) | Anticuerpos dirigidos contra il-11ra | |
| CY1125327T1 (el) | Anti-pd-1 αντισωματα και συνθεσεις | |
| IL282886A (en) | Methods and combinations for treatment and t cell modulation | |
| IL283325A (en) | Methods for treatment using adoptive cell therapy | |
| MA51631A (fr) | Anticorps anti-pd1 et méthodes de traitement | |
| BR112019002331A2 (pt) | anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos | |
| CL2018000728A1 (es) | Anticuerpos anti-cd19 humano humanizados y métodos de utilización | |
| EP3891175A4 (en) | MODIFIED PROTEINS AND RELATED TREATMENT METHODS | |
| MA52962A (fr) | Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1 | |
| MA52789A (fr) | Méthodes de traitement du cancer avec des anticorps anti-pd-1 | |
| IL287423A (en) | Antibodies and methods for treatment of influenza a infection | |
| MX2021010665A (es) | Metodos de tratamiento de amiloidosis al. | |
| CO2019004561A2 (es) | Métodos de tratamiento de una lesión renal aguda | |
| IL291725A (en) | Methods and compositions for treating diabetic retinopathy | |
| IL281775A (en) | Methods of treatment of infections using bacteria | |
| EP4355238A4 (en) | ELECTROPORATION TREATMENT | |
| EP3743057A4 (en) | TREATMENT OF HEARING LOSS | |
| IL281839A (en) | Treatment methods | |
| IL281792A (en) | Treatment methods | |
| EA202191779A1 (ru) | Способ получения антраниламидов | |
| IL289242A (en) | Combination therapy methods, compositions and kits | |
| IL283564A (en) | Radiation-treated fibers, methods of treating and applications for use | |
| IL313079A (en) | Methods of treatment using lou064 | |
| EA201891351A1 (ru) | Вспениваемая композиция галобетазола и способ её применения |